Recent advances in dermatologic therapy include the use of imiquimod
beyond its original use as a treatment for anogenital condylomata acuminata.
Another immunomodulating drug, tacrolimus, has been used topically to treat
a variety of dermatoses. New concepts in the management of toxic epidermal
necrolysis will also be discussed.
Stanley MA.Mechanism of action of imiquimod. Papillomavirus Rep.1999;10:23-29.
Edwards L, Ferenczy A, Eron L.
et al. Self-administered topical 5% imiquimod cream for external anogenital
warts. Arch Dermatol.1998;134:25-30.
Tyring SK, Arany I, Stanley MA.
et al. A randomized, controlled, molecular study of condylomata acuminata
clearance during treatment with imiquimod. J Infect Dis.1998;178:551-555.
Sidky YA, Borden EC, Weeks CE.
et al. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res.1992;52:3528-3533.
Syed T, Goswami J, Ahmadpour O.
et al. Treatment of molluscum contagiosum in males with an analog of imiquimod
1% in cream: a placebo-controlled, double-blind study. J Dermatol.1998;25:309-313.
Weeks CE, Gibson SJ.Induction of interferon and other cytokines by imiquimod and its hydroxylated
metabolite R-842 in human blood cells in vitro. J Interferon Res Cytokine.1994;14:81-85.
Ruzicka T, Assmann T, Homey B.Tacrolimus: the drug for the turn of the millennium? Arch Dermatol.1999;135:574-580.
de Paulis A, Stellato C, Cirillo R.
et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol.1992;99:723-727.
Reich K, Vente C, Neumann C.Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol.1998;139:755-757.
Ruzicka T, Bieber T, Schopf E.
et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med.1997;337:816-821.
Zonneveld IM, Rubins A, Jablonska S.
et al. Topical tacrolimus is not effective in chronic plaque psoriasis. Arch Dermatol.1998;134:1101-1102.
Roujeau JC, Kelly J, Naldi L.
et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal
necrolysis. N Engl J Med.1995;333:1600-1607.
Rzany B, Correia O, Kelly JP.
et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during
first weeks of antiepileptic therapy: a case control study. Lancet.1999;353:2190-2194.
Kelemen J, Cioffi W, McManus W.
et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg.1995;180:273-278.
McGee T, Munster A.Toxic epidermal necrolysis syndrome: mortality rate reduced with early
referral to regional burn center. Plast Reconstr Surg.1998;102:1018-1022.
Halebian P, Madden M, Finklestein J.
et al. Improved burn center survival of patients with toxic epidermal necrolysis
managed without corticosteroids. Ann Surg.1986;204:503-512.
Egan C, Grant W, Morris S.
et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol.1999;40:458-461.
Chaidemenos G, Chrysomallis F, Sombolos K.
et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol.1997;36:218-221.
Heng MC, Allen SG.Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol.1991;25:778-786.
Viard I, Wehrli P, Bullani R.
et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human
intravenous immunoglobulin. Science.1998;282:490-493.
Rzany B, Hering O, Mockenhaupt M.
et al. Histopathological and epidemiological characteristics of patients with
erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal
necrolysis. Br J Dermatol.1996;135:6-11.
Wolkenstein P, Adle H, Wechsler J.
et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol.1996;134:710-714.
Wolkenstein P, Latarjet J, Roujeau JC.
et al. Randomised comparison of thalidomide versus placebo in toxic epidermal
necrolysis. Lancet.1998;352:1586-1589.